학술논문
Preliminary Safety and Efficacy Results from TOPAZ-II: A Phase 3b Study Evaluating Long-Term Clinical Outcomes in HCV Genotype 1-infected Patients Receiving Ombitasvir/Paritaprevir/r and Dasabuvir plus / -Ribavirin
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15273350